Anchiano Therapeutics, a Phase 3 biotech developing therapies for early-stage bladder cancer, filed on Monday with the SEC to raise up to $35 million in an initial public offering. Insiders intend to purchase up to $17.5 million of the IPO (50% of the deal).
The Jerusalem, Israel-based company was founded in 2004 and plans to list on the Nasdaq under the symbol ANCN. Anchiano Therapeutics filed confidentially on September 22, 2018. Oppenheimer & Co. is the sole bookrunner on the deal. No pricing terms were disclosed.
